L’anticorps anti-ANKRD30A Polyclonal Lapin est utilisé pour la détection de ANKRD30A dans des échantillons de Humain. Il a été validé pour WB, ELISA, IHC et IF.
Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB 1:500-1:2000,IHC 1:100-1:300,ELISA 1:5000,IF 1:50-200
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
Liquid in PBS containing 50 % glycerol, 0.5 % BSA and 0.02 % sodium azide.
Agent conservateur
Sodium azide
Précaution d'utilisation
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Stock
-20 °C
Stockage commentaire
Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.
Date de péremption
12 months
Antigène
ANKRD30A
(Ankyrin Repeat Domain 30A (ANKRD30A))
Autre désignation
ANKRD30A
Sujet
ANKRD30A, Ankyrin repeat domain-containing protein 30A, Serologically defined breast cancer antigen NY-BR-1Ankyrins are membrane adaptor molecules that play important roles in coupling integral membrane proteins to the spectrin-based cytoskeleton network. Mutations of ankyrin genes lead to severe genetic diseases, such as fatal cardiac arrhythmias and hereditary spherocytosis. ANKRD30A (ankyrin repeat domain 30A), also known as serologically defined breast cancer antigen NY-BR-1, is a 1,397 amino acid coiled-coil protein. Containing six ANK repeats and thirty-seven exons, ANKRD30A is a distant homolog of the POTE family. Initiated by either Dnmt1 or Met-57, ANKRD30A is highly expressed in breast and testis, and faintly in placenta. Present in 80 % of breast cancers, but not in other types of tumors, ANKRD30A is a differentiation antigen and a potential target for antibody-based therapies in breast cancers.